LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Search

Phreesia Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

11.88 0.42

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

11.87

Max

12.3

Pagrindiniai rodikliai

By Trading Economics

Pajamos

3.6M

4.3M

Pardavimai

3.1M

120M

Pelno marža

3.549

Darbuotojai

2,082

EBITDA

6.1M

13M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+135.15% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-03-11

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-469M

737M

Ankstesnė atidarymo kaina

11.46

Ankstesnė uždarymo kaina

11.88

Naujienos nuotaikos

By Acuity

50%

50%

127 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Phreesia Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-15 23:21; UTC

Įsigijimai, susijungimai, perėmimai

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

2026-02-15 23:45; UTC

Rinkos pokalbiai

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

2026-02-15 23:40; UTC

Rinkos pokalbiai

Gold Falls on Possible Position Adjustments -- Market Talk

2026-02-15 23:06; UTC

Uždarbis

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

2026-02-15 23:04; UTC

Uždarbis

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

2026-02-15 23:04; UTC

Uždarbis

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

2026-02-15 23:01; UTC

Uždarbis

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

2026-02-15 23:01; UTC

Uždarbis

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

2026-02-15 22:53; UTC

Įsigijimai, susijungimai, perėmimai

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

2026-02-15 22:53; UTC

Įsigijimai, susijungimai, perėmimai

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

2026-02-15 22:52; UTC

Įsigijimai, susijungimai, perėmimai

Qube Shareholders to Receive A$5.20/Share in Cash

2026-02-15 22:52; UTC

Įsigijimai, susijungimai, perėmimai

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

2026-02-15 22:22; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope CEO Tania Archibald Speaking on a Call With Media

2026-02-15 22:17; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope CEO: Stresses Whyalla Project Would Have to Make Sense to Shareholders

2026-02-15 22:16; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope CEO: Some Job Cuts Inevitable to Ensure Company is Competitive

2026-02-15 22:14; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope CEO: Higher Returns Tied to End of Capital Investment Program

2026-02-15 22:14; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope Steel CEO: Higher Returns After Rebuffed Takeover Bid a 'Natural Coincidence'

2026-02-15 20:48; UTC

Uždarbis

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

2026-02-15 20:47; UTC

Uždarbis

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

2026-02-15 20:46; UTC

Uždarbis

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

2026-02-15 20:45; UTC

Uždarbis

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

2026-02-15 20:44; UTC

Uždarbis

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

2026-02-15 20:44; UTC

Uždarbis

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

2026-02-15 20:43; UTC

Uždarbis

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

2026-02-15 20:42; UTC

Uždarbis

BlueScope Net Debt A$2.2 Million at Dec. 31

2026-02-15 20:42; UTC

Uždarbis

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

2026-02-15 20:41; UTC

Uždarbis

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

2026-02-15 20:40; UTC

Uždarbis

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

2026-02-15 20:40; UTC

Uždarbis

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

2026-02-15 20:39; UTC

Uždarbis

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

Akcijų palyginimas

Kainos pokytis

Phreesia Inc Prognozė

Kainos tikslas

By TipRanks

135.15% į viršų

12 mėnesių prognozė

Vidutinis 28.1 USD  135.15%

Aukščiausias 35 USD

Žemiausias 22 USD

Remiantis 12 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Phreesia Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

12 ratings

12

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

25.23 / 25.61Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Strong Bullish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

127 / 351 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Phreesia Inc

Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, an on-site kiosks. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is based in Wilmington, Delaware.
help-icon Live chat